Background. Data regarding antimicrobial susceptibility of clinical Lactobacillus isolates are scarce, and appropriate interpretation criteria for susceptibility tests are not available.
Lactobacilli are ubiquitous commensals of the normal human flora and are only occasionally found in clinical infections [1] . These organisms should be considered to be significant if they are isolated from sterile sites, such as blood [2] [3] [4] , peritoneal fluid [5, 6] , or other deep foci [7, 8] . Lactobacilli may be difficult to culture, and use of specific culture media has been suggested [9, 10] . Conventional identification methods reveal only 30%-50% of the isolates [11, 12] . Furthermore, identification of lactobacilli at the species level is often difficult, and the taxonomy has been changing over the past decade [10, 12, 13] . Accurate identification of lactobacilli at the species level requires molecular analysis of the 16S rRNA gene [14] .
The antimicrobial susceptibility of lactobacilli has received only little attention, and clinical isolates have rarely been studied. Most of the studies have included only a limited number of Lactobacillus strains representing different species. Susceptibility to antimicrobial agents shows wide differences among Lactobacillus species and is often species dependent [15] [16] [17] . For example, some species, such as Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus curvatus, and Lactobacillus fermentum, are inherently resistant to glycopeptides [17] , in contrast to the susceptible Lactobacillus acidophilus group and Lactobacillus delbrüeckii [18] . In our previous survey of 89 patients with Lactobacillus bacteremia, the data suggested that appropriate antimicrobial therapy would be associated with reduced mortality [4] .
In the present study, we analyzed and evaluated the significance of antimicrobial susceptibilities of clinical Lactobacillus blood isolates characterized at the species level. The isolates were obtained from a large number of patients with bacteremia. We also evaluated the possible correlation of the E-test and disk diffusion test methods and compared the correlation with the clinical treatment results and with the outcomes of the patients.
MATERIALS AND METHODS

Isolates and patients.
A total of 86 patients with a Lactobacillus isolate cultured from a blood sample were included. Between 1989 and 2004, blood culture isolates were collected at Helsinki University Central Hospital (Helsinki, Finland), and between 1994 and 2000, isolates were collected at microbiological laboratories throughout Finland, as described elsewhere [19] . In addition to the 47 isolates from the previously collected material [4, 19] , 39 additional Lactobacillus blood isolates were included. Patient records of all 86 blood culture-positive individuals were collected and reviewed. Clinical manifestations and outcomes of patients were recorded. Endocarditis was diagnosed according to the Dukes criteria [20] . Special attention was paid to any possible antimicrobial therapy received prior to the bacteremic event (receipt of therapy !2 weeks prior to the event or receipt of ongoing treatment). The duration and the adequacy of treatment were assessed. The antimicrobial treatment was regarded as adequate if the duration of therapy was у7 days and the isolate was regarded as susceptible in vitro to at least 1 antimicrobial agent being used. In addition to the clinical Lactobacillus isolates, the probiotic L. rhamnosus GG strain (ATCC 53103; provided by Valio) was included in the susceptibility tests.
Identification of the isolates. Isolates were stored until analysis at Ϫ70ЊC. Bacterial strains were grown anaerobically at 37ЊC on MRS-agar (LabM; International Diagnostics Group) or on Trypcase Soy agar (BioMérieux) supplemented with 5% horse blood. Preliminary characterization of the Lactobacillus isolates was performed according to their carbohydrate fermentation profile, using API 50 CH strips and APILAB Plus software, version 4.0 (BioMérieux). Identification was confirmed by species-specific PCR or by partial sequencing of 16S rDNA, as described elsewhere [4, 19] . All L. rhamnosus strains were compared with L. rhamnosus GG by means of PFGE, as described elsewhere [19] . Four restriction enzymes-NotI, SfiI, AscI, and FseI-were used separately to cut the genomic DNA of the strains. The PFGE profile of L. rhamnosus GG was used as a control with every sample. The PFGE patterns of the strains were compared visually, and isolates with PFGE patterns identical to that of L. rhamnosus GG were regarded as L. rhamnosus GG type (i.e., indistinguishable from L. rhamnosus GG).
Antimicrobial susceptibility tests. The antimicrobial susceptibilities of 85 clinical Lactobacillus blood culture isolates and L. rhamnosus GG were tested with the E-test method, as described elsewhere [4] . The antimicrobial agents studied were benzylpenicillin, ampicillin, cephalotine, cefuroxime, ceftriaxone, imipenem, vancomycin, netilmycin, tobramycin, erythromycin, clindamycin, piperacillin-tazobactam, ciprofloxacin, doxycycline, and metronidazole. Wilkins-Chalgren anaerobe agar plates (Oxoid) supplemented with menadione (Sigma) and 5.5% sheep blood were inoculated, and E-test strips were added. MICs were determined after incubation in a microaerobic atmosphere at 37ЊC for 24 h. Staphylococcus aureus ATCC 29213 and Escherichia coli 25922 were included as control organisms. In addition, using the same agar plates and incubation conditions mentioned above, disk diffusion tests (Oxoid) were performed for vancomycin (30 mg disk), clindamycin (2 mg disk), erythromycin (15 mg disk), penicillin (10 mg disk), imipenem (10 mg disk), cephalotine (30 mg disk), ampicillin (10 mg disk), and metronidazole (5 mg disk). Statistical analysis. The x 2 test or Fisher's exact test was used for nominal variables. Kaplan-Meier survival curves for survival after the onset of bacteremia and the log-rank test were used to compare groups on the basis of adequacy of treatments. The survival curves were also compared using the Cox regression model, in which the McCabe classification and Lactobacillus groups were included as additional explaining variables. Any P value !.05 was considered to be statistically significant. Data were analyzed using SPSS, version 12.0 (SPSS).
RESULTS
Among the 86 clinical
Lactobacillus blood culture isolates that were collected, 11 different species were found. One Lactobacillus salivarius isolate failed to grow sufficiently on the WilkinsChalgren media and was not included in the susceptibility tests. Other antimicrobial agents. The growth of all Lactobacillus isolates was inhibited by р0.25 mg/mL of erythromycin, and the majority of them also had clindamycin MICs р0.5 mg/mL (tables 2 and 3). Low MICs (р1 mg/mL) for ciprofloxacin were observed among all L. rhamnosus GG type isolates, but MICs were higher for L. fermentum, L. gasseri, L. plantarum, and L. reuteri isolates.
Benzylpenicillin
Lactobacillus curvatus
Vancomycin MICs were у256 mg/mL for all Lactobacillus species, except for L. jensenii and L. gasseri, which demonstratred low MICs by E-test and clear inhibition zones by the disk diffusion test (tables 2 and 3). MICs of tobramycin were higher than those of netilmycin for all Lactobacillus isolates. The antimicrobial susceptibility pattern for the probiotic L. rhamnosus GG strain was similar to those of clinical L. rhamnosus GG type isolates and other L. rhamnosus blood isolates (data not shown).
Disk Diffusion Tests
In disk diffusion tests, imipenem, erythromycin, and clindamycin produced large inhibition zones for the 85 tested isolates, in accordance with low MICs by E-tests ( figure 1 ). On the other hand, a somewhat higher variation of inhibition zone for ampicillin was observed (clearly, there was a higher variation for penicillin and an especially high variation for cephalosporins). No inhibition was observed for metronidazole or for vancomycin, except for clear inhibition zones observed for vancomycin by L. jensenii (23-34 mm) and L. gasserii (22-29 mm) isolates, which was in accordance with the E-test results.
Antimicrobial Treatment Prior to Lactobacillus Bacteremia
One-half of the patients were receiving antimicrobial treatment during the 2 weeks preceding Lactobacillus bacteremia, and 42% of the patients were treated on the very same day that blood culture revealed Lactobacillus (table 4) . Patients in the L. rhamnosus group were receiving an ongoing antimicrobial regimen at the time that the bacteremic event occurred more often than were patients infected with other lactobacilli (54% vs. 28%;
, by the x 2 test). Lactobacillus species was found in blood P p .012 cultures of 15% of patients receiving ongoing treatment that included an antimicrobial agent to which the isolated bacteria was presumably susceptible (on the basis of E-test results). Of these particular breakthrough bacteremic patients, 4 were receiving ongoing carbapenem treatment, and the isolated lactobacilli demonstrated low MICs of imipenem (MIC range, 1.0-2.0 mg/mL). All of these patients had severe underlying diseases, and 3 of them died within 1 week after onset of bacteremia. Cephalosporins were used in the treatment of 20 patients (24%) 2 weeks prior to their bacteremic events and in the treatment of 12 patients (14 %) on the day of positive blood culture results. Lactobacilli isolated from these patients demonstrated high MICs (1256 mg/mL) of ceftriaxone and, in most cases, relatively high MICs (range, 2-96 mg/mL) of cephalotine as well.
Antimicrobial Treatment of Lactobacillus Bacteremia
For 55% of patients, clinicians changed the antimicrobial treatment according to results of the susceptibility tests performed Figure 1 . Relationship between imipenem, cephalotine, erythromycin, and ampicillin MICs according to the E-test and the zone diameters according to disk diffusion for the 85 Lactobacillus isolates. Please note the variable scale of the x-axis.
by the local microbiological laboratories. Only 4 of 86 patients with Lactobacillus bacteremia did not receive any antimicrobial therapy at all. Combination therapy with у2 antimicrobial agents was used in 83% of the patients (table 4) . In 54% of them, however, the additional antimicrobial agent was metronidazole or vancomycin, which were ineffective for lactobacilli in vitro. The treatment was regarded as presumably adequate in 81% of patients, on the basis of E-test results. The mean duration (‫ע‬SD) of antimicrobial therapy was 12.9 ‫ע‬ days (range, 1-60 days). The adequacy of treatment was 14.3 not found to be associated with mortality at 7 days or at 1 month (table 5) .
Six (38%) of 16 patients who presumably received inadequate treatment (on the basis of E-test results) died within 1 month, whereas mortality in adequately treated patients was 23% ( ). According to the Cox regression model, adjusted P p .411 for McCabe classification and Lactobacillus groups, adequate treatment was not found to be significantly associated with lower mortality (OR, 0.82; 95% CI, 0.36-1.87;
). Po-P p .636 lymicrobial bacteremia was found in 29% of patients overall and was found more often in patients infected with Lactobacillus species other than L. rhamnosus (19.6% vs. 40%;
). P p .037 Only 2 patients with endocarditis were detected. One of them had mitral regurgitation and bacteremia due to L. jensenii.
DISCUSSION
To the best of our knowledge, this study presents the largest collection of Lactobacillus blood culture isolates identified at the species level and tested for antimicrobial susceptibility. With the E-test method, all isolates demonstrated low MICs of imipenem, piperacillin-tazobactam, erythromycin, clindamycin, and netilmycin, in accordance with previous data [21] . The ranges for the MICs of cephalosporins, which are frequently used to treat bacteremic infections, were wide, and very high MICs were demonstrated for many isolates. In general, the second-generation cephalosporin, cefuroxime, showed higher activity against lactobacilli, compared with the third-generation cephalosporin, ceftriaxone, which is in accordance with earlier observations [22] .
Antimicrobial treatment with broad-spectrum cephalosporins and glycopeptides has been speculated to predispose immunocompromised patients to Lactobacillus infection [25, 26] . In our study, one-half of the patients received antimicrobial therapy during 2 weeks before the onset of Lactobacillus bacteremia, and, in 22% of patients, the blood isolate was presumably susceptible to the antimicrobial regimen. In these breakthrough cases of bacteremia, cephalosporins were given to 23% of patients, and other b-lactam agents were given to 33% of patients, whereas vancomycin was given to only 11% of patients, in contrast to previous reports [12] . The wide variability in susceptibility for cephalosporins, even within 1 species, together with the high number of breakthrough cases of bacteremia that occurred during receipt of cephalosporin therapy, suggests that Lactobacillus bacteremia might not be treated effectively with cephalosporins.
The genus Lactobacillus is large, and its antimicrobial susceptibility seems to be species dependent. This was also true for several antimicrobial agents in our study, because there was a clear variation in the susceptibility results for different Lac-tobacillus species. Vancomycin MICs have been shown to be species related [12, 16, 21, 23, 24] , a finding that was also demonstrated by the present study. Low vancomycin MICs were detected for L. gasseri and L. jensenii (range, 0.75-1.5 mg/mL), which were similar to those for the L. acidophilus group, but for all other species the MICs were very high (у256 mg/mL).
Susceptibility data regarding clinical Lactobacillus blood isolates are scarce, despite the existence of some solitary case reports. There are neither golden standards for susceptibility testing of Lactobacillus isolates nor approved guidelines for interpreting test results. In the present study, breakpoints used for staphylococci were chosen while the criteria for adequate antimicrobial treatment were being considered. However, these breakpoints may be too low for the interpretation of benzylpenicillin and ampicillin MICs (!0.12 mg/mL and !0.25 mg/ mL, respectively) if they are compared with susceptibilities found in this study and in previous studies that clearly demonstrate higher MICs of ampicillin (0.5-4 mg/mL) and benzylpenicillin (1-8 mg/mL) [16, 17, 23, 27] . Successful penicillin treatment, although combined with aminoglycoside, has been reported previously in patients with Lactobacillus bacteremia [3, 28, 29] . In our study, data regarding antimicrobial treatment and the outcome of patients were available. However, the appropriate interpretation criteria for results of the susceptibility tests and the impact on the outcome of patients were difficult to determine, because 82% of the patients were treated with у1 antimicrobial agent. Furthermore, Lactobacillus bacteremia is most common among patients with severe fatal underlying diseases, as was the case for 41% of patients in this study. This may also be reflected in the findings of the present study, which showed that according to the E-test results, although mortality at 1 week was 12% among patients who presumably received adequate treatment and 27% among patients who plausibly received inadequate treatment, no significant difference could be found, which differs from findings of our previous study [4] . In the present study, the absolute number of lethal cases was low, resulting in low statistical power. The relatively large number of patients with rapidly fatal underlying diseases dilutes the beneficial effects of the antimicrobial treatment in both studies, underscoring the need for a very large number of patients to detect small differences in clinical outcome. Overall mortality at 1 month was only 26% in our study, compared with that observed by Husni and colleagues, who reported a 44% mortality during hospitalization of patients [3] , suggesting that microbiologically guided treatment might still be preferential for Lactobacillus bacteremia.
For agents with good susceptibility among lactobacilli, results of the disk diffusion test seemed to correlate well with E-test results. However, susceptibilities to cephalosporins were variable, even within 1 species, suggesting that cephalosporins would not be the ideal treatment for Lactobacillus bacteremia.
